Dental Implants and Bisphosphonates: What UK Dentists Ask

Bisphosphonates dental implants is one of the trickiest medical histories UK clinics handle. The drugs strengthen bone but slow the remodelling implants depend on. Most oral bisphosphonate patients can still have implants safely. Intravenous users face higher BRONJ risk. A careful consultation, scans and written consent are non negotiable.

TL;DR. Bisphosphonates dental implants decisions in the UK in 2026 hinge on which drug, what dose, how long and which route. Oral Fosamax for under 4 years carries low BRONJ risk and most clinics will treat. Intravenous zoledronic acid for cancer is high risk and most UK surgeons decline routine implants. Expect a detailed medical history, CBCT scan, possible GP letter and a written consent form. Implant survival on oral bisphosphonates is reported at 95 to 97 per cent at 5 years on PubMed studies, broadly in line with the general population.

Bisphosphonates dental implants: the short UK answer

Bisphosphonates are a family of drugs that bind to bone and slow the cells that break it down. Patients in the UK take them for osteoporosis, Paget disease, multiple myeloma and cancer that has spread to bone. The most common brand names in dental notes are Fosamax (alendronate), Actonel (risedronate), Boniva (ibandronate) and Zometa or Aclasta (zoledronic acid).

The General Dental Council (GDC) holds UK clinicians to the same standard of care for medically complex patients as for anyone else. The Royal College of Surgeons of England Faculty of Dental Surgery (RCS Eng) and the British Dental Association (BDA) publish guidance on medication related osteonecrosis of the jaw, known as MRONJ, with bisphosphonate related osteonecrosis (BRONJ) as the most studied subset. In short, your dentist must risk stratify you before any extraction or implant.

The headline UK position in 2026: oral bisphosphonates for under 4 years and no other risk factors put you in the low risk group, and implants are usually offered. Intravenous bisphosphonates for cancer or denosumab use put you in the higher risk group, where most UK surgeons either decline implants or treat only in a hospital setting after multidisciplinary review.

What bisphosphonates actually do to bone

Bone is constantly remodelling. Osteoclasts dissolve old bone, osteoblasts lay down new bone. Bisphosphonates bind to the bone surface and inhibit osteoclasts, slowing the turnover. For an osteoporosis patient this reduces fracture risk. For an implant patient it changes the wound healing environment.

Implants rely on a process called osseointegration, the biological knitting of bone to titanium. Our explainer on osseointegration and the biology behind a lasting dental implant covers the cellular detail. The concern with bisphosphonates is twofold. First, bone may struggle to remodel around the fixture in the months after placement. Second, if the surrounding tissue is injured, the bone may fail to heal and the surface dies, producing the exposed dead bone known as BRONJ.

In practice, oral bisphosphonates rarely produce BRONJ. Intravenous bisphosphonates for cancer carry a much higher risk because the cumulative dose is far greater and the drug accumulates in jawbone for years.

BRONJ and MRONJ explained for UK patients

BRONJ stands for bisphosphonate related osteonecrosis of the jaw. MRONJ is the broader term, covering denosumab and antiangiogenic drugs too.

The clinical definition adopted across UK practice requires three things: exposed bone in the mouth that has not healed after 8 weeks, current or previous treatment with the drug, and no history of jaw radiotherapy.

Lifetime BRONJ risk after dental surgery in oral bisphosphonate patients is reported at around 0.01 to 0.1 per cent on PubMed reviews. For intravenous cancer patients the same risk can climb to 1 to 15 per cent depending on dose and duration.

Common UK bisphosphonates and their risk profile

UK dentists ask which drug, what dose, how long and how it is taken.

Fosamax (alendronate). Oral, weekly, for osteoporosis. Fosamax dental implant risk is low under 4 years of use.
Actonel (risedronate). Oral, weekly or monthly. Similar profile to alendronate.
Boniva (ibandronate). Oral monthly or IV every 3 months. Oral form low risk, IV form moderate.
Zometa, Aclasta (zoledronic acid). IV once yearly for osteoporosis or every 3 to 4 weeks in cancer. The cancer dose carries the highest BRONJ risk.
Aredia (pamidronate). IV, used mainly in cancer and Paget disease. High risk.

If you are unsure which drug you take, your GP records or repeat prescription slip will list it.

Oral vs intravenous bisphosphonates: the risk gap

Route of administration matters more than almost any other factor.

Oral bisphosphonates. Cumulative bone dose is modest. Most UK clinics treat without hospital referral if duration is under 4 years and no other risk factors apply.
IV for osteoporosis. Once yearly Aclasta is intermediate risk. Many UK clinics will still consider implants after careful planning.
IV for cancer. Frequent Zometa or Aredia carries the highest BRONJ risk. Most UK private surgeons decline routine implants and refer to hospital.

For broader bone biology in older patients, our review of dental implants for women over 50 and how hormones affect bone outcomes is useful, as many bisphosphonate users are post menopausal women.

What UK dentists ask before implant surgery

Expect a structured medical history and a written record. Typical questions in a UK consultation include:

Which bisphosphonate are you taking, and what is the brand name?
Is it oral or intravenous?
What dose and how often?
When did you start, and have you stopped at any point?
Why were you prescribed it, osteoporosis or cancer?
Are you also on steroids, chemotherapy or denosumab (Prolia, Xgeva)?
Have you had any previous extractions, and how did they heal?
Do you smoke, and how is your diabetic control if relevant?

The clinic will likely write to your GP or specialist for confirmation. They will also perform a cone beam CT scan to map your bone, which we cover in our explainer on why a CBCT scan matters and what it costs in the UK in 2026. Nothing is signed off without these checks in 2026 UK practice.

If the clinic skips the medical history or pushes a same day implant on a Fosamax patient with no scan, that is a red flag. Our checklist on how to spot a dodgy dental implant quote in 30 seconds covers warning signs in plainer language.

Drug holidays: do you need to stop bisphosphonates before implants?

For oral bisphosphonates under 4 years, most UK guidance does not require a drug holiday. The half life in bone is measured in years, so a short pause provides little protection and may raise fracture risk for the underlying condition.

For oral use over 4 years, or any other BRONJ risk factor, some UK specialists recommend a 2 to 3 month drug holiday, agreed with the prescribing GP. Evidence on benefit is mixed on PubMed and the decision is individual.

For IV bisphosphonates in cancer, holidays are usually not feasible. These cases stay in hospital units.

Never stop a prescribed bisphosphonate on your own. Discuss timing with both the prescriber and the implant surgeon. Our piece on dental implants after 60 and what changes gives wider context on coordinating care.

Implant success rates on bisphosphonates: what the UK data shows

UK and European outcomes are reassuring for the low risk group. Peer reviewed studies indexed on PubMed report implant survival of:

Oral bisphosphonate users, low risk profile. 95 to 97 per cent at 5 years, broadly in line with the general UK population.
Oral bisphosphonate users over 4 years, no holiday. 92 to 95 per cent at 5 years.
IV bisphosphonate users for osteoporosis. 88 to 93 per cent at 5 years, with closer follow up.
IV bisphosphonate users for cancer. Limited data, most studies report on hospital based cohorts and BRONJ rates are the main outcome measured rather than survival.

For the wider context on how long implants last and which factors matter most, our 2026 review of how long dental implants last in the UK is the companion piece. If a failure does happen, the reasons and next steps are covered in dental implant failure rates and what to do next.

Practical steps if you take bisphosphonates and want implants

A short UK action list for 2026.

Bring your prescription details. Drug name, dose, route, start date, current status.
Ask the clinic for written risk stratification. Low, moderate or high should appear in the notes.
Insist on a cone beam CT scan. Two dimensional X rays are not enough.
Confirm the surgical protocol. Atraumatic technique, primary closure, antibiotic cover and antiseptic mouthwash all reduce BRONJ risk.
Get a GP letter if duration is over 4 years. The prescriber confirms whether a holiday is appropriate.
Plan follow up. Reviews at 1, 4, 12 and 24 weeks, then 6 monthly.
Treat extractions first if possible. Letting sockets heal under bisphosphonates is safer than combining extraction and implant in one visit.
Maintain meticulous hygiene. Peri implantitis is harder to treat on this background.

If grafting is needed, our explainers on bone augmentation techniques in UK clinics and on whether you really need a bone graft before an implant help you weigh options. Many bisphosphonate patients overlap with dental implants with osteoporosis in the UK. Guided surgery is often suggested because it minimises bone trauma, as covered in guided implant surgery in the UK.

Cost and NHS access for higher risk patients

NHS England funds dental implants only for severe medical need such as head and neck cancer reconstruction, cleft palate or major trauma, as set out in the NHS dental costs guidance. A bisphosphonate user with simple tooth loss is not eligible for NHS funded implants on those grounds alone. Most patients in 2026 fund implants privately.

Private fees for bisphosphonate patients are usually quoted at the standard band, although a few specialist hospital based centres charge a premium for higher complexity cases. Typical 2026 ranges:

Single implant with crown, low risk oral bisphosphonate patient: £2,200 to £3,500.
Single implant with crown, moderate risk patient with hospital based planning: £3,000 to £4,500.
Full arch fixed bridge, high risk patient: rarely offered privately, usually NHS hospital pathway.

The full price context sits in our 2026 dental implants cost UK breakdown.

For implant insurance and finance considerations, ask early. Some plans exclude pre existing medical conditions that materially raise risk. A written treatment plan, signed consent form and itemised quote are the standard UK paperwork. Get at least two quotes from GDC registered providers before signing anything. Our free service at /#quote-form connects bisphosphonate patients with vetted UK clinics that handle medically complex cases.

Frequently asked questions

Can you have dental implants if you take Fosamax in the UK?

Yes, in most low risk cases. UK guidance treats oral alendronate (Fosamax) under 4 years of use, with no steroids, no chemotherapy and no smoking, as low risk for BRONJ. Implants are usually offered after a cone beam CT scan, written consent and confirmation from your GP. Fosamax dental implant risk rises with longer duration, higher dose and additional medical factors, so the consultation must record all of these. Survival rates on PubMed are reported at 95 to 97 per cent at 5 years for this group, broadly in line with the general UK population.

What is the difference between BRONJ and MRONJ?

BRONJ is bisphosphonate related osteonecrosis of the jaw. MRONJ is the broader category, medication related osteonecrosis of the jaw, which also includes denosumab (Prolia, Xgeva) and antiangiogenic drugs used in cancer. UK clinical guidance has shifted to use MRONJ in records, but BRONJ remains common in patient leaflets. Diagnostic criteria are the same: exposed bone for more than 8 weeks, history of the drug and no jaw radiotherapy. The Royal College of Surgeons of England Faculty of Dental Surgery (RCS Eng) treats both as a single risk category for planning.

Do I need to stop my bisphosphonate before implant surgery?

Usually not for oral drugs under 4 years. The drug binds to bone and remains there for years, so a short pause does not meaningfully empty the jaw of bisphosphonate. Stopping the drug also raises fracture risk for the underlying osteoporosis. For oral use over 4 years or any IV use, some UK specialists negotiate a 2 to 3 month drug holiday with the prescribing GP. Never stop a prescribed bisphosphonate without medical advice. The British Dental Association (BDA) supports a shared decision with the prescriber, not a unilateral pause by the dental clinic.

How risky are dental implants for cancer patients on IV bisphosphonates?

High enough that most UK private surgeons decline routine implants. Patients on Zometa or Aredia for myeloma, breast cancer or prostate cancer carry BRONJ rates reported between 1 and 15 per cent on PubMed studies, depending on dose and duration. These cases are usually managed in NHS hospital units, where multidisciplinary planning, hyperbaric oxygen review and conservative options like fixed bridges are considered first. NHS funding may apply if implants are part of cancer reconstruction, as covered by the NHS dental costs guidance.

What if I am on both bisphosphonates and steroids?

Concurrent steroids meaningfully raise BRONJ risk and push you into the moderate or high category in most UK risk frameworks. Long term prednisolone for rheumatoid arthritis, polymyalgia rheumatica or asthma should be declared at the consultation. Expect a written letter to your GP, a more cautious surgical protocol and tighter follow up at 1, 4, 12 and 24 weeks post surgery. The General Dental Council (GDC) holds the clinician responsible for documenting this risk stratification before placement.

Are mini implants safer for bisphosphonate patients than standard implants?

Sometimes, in the lower denture stabilisation indication, because the flapless surgical technique reduces bone trauma. They are not a universal substitute and are not appropriate for molar single tooth replacement or full arch fixed bridges on these patients. The decision should follow the same medical history and CBCT planning as for a standard implant. Our guide on mini dental implants in the UK in 2026 and when they work covers the indications in detail.

Will the NHS pay for implants if I am a bisphosphonate patient?

NHS England funds dental implants only for severe medical need. A bisphosphonate prescription alone does not qualify. Eligibility usually requires head and neck cancer reconstruction, cleft palate, major trauma or congenital tooth absence. Most bisphosphonate patients who want implants in 2026 fund them privately, after a clear written consent form and a risk stratification. If you are also being treated for jaw cancer or have undergone hospital reconstruction, ask your maxillofacial team whether implants are part of your funded pathway. Full UK eligibility detail sits in the NHS dental costs guidance.